Journal of Urology: Vol 210, No 2
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t sign in? Forgot your username?
Related Articles
MP75-09âHOW NOCTURIA CAN HELP A UROLOGIST DIAGNOSE A SLEEP DISORDER | Journal of Urology
INTRODUCTION AND OBJECTIVE:There is a well-established association between obstructive sleep apnea (OSA) and nocturia. However, it is not common practice for nocturia patients to receive…
MP76-06âIMPACT OF DOBBS v. JACKSON WOMENâs HEALTH ORGANIZATION ON INCIDENCE OF CHILDLESS AND PARTNERLESS VASECTOMY | Journal of Urology
INTRODUCTION AND OBJECTIVE:The Supreme Court ruling Dobbs v. Jackson Womenâs Health Organization (June 2022) overturned federal protection of abortion rights, significantly impacting female and male…
PD60-04ââLINK IN MY BIOâ: COMMERCIAL BIAS IN ERECTILE DYSFUNCTION TREATMENT VIDEOS ON SOCIAL MEDIA PLATFORMS | Journal of Urology
INTRODUCTION AND OBJECTIVE:Patients are increasingly turning to social media platforms for health information, particularly on sensitive topics like erectile dysfunction (ED) treatment. Social media âinfluencersâ…
MP68-09âTHE ASSOCIATION BETWEEN 5-ALPHA REDUCTASE INHIBITORS AND PROSTATE CANCER MORTALITY | Journal of Urology
INTRODUCTION AND OBJECTIVE:5-alpha-reductase-inhibitors (5-ARIs), finasteride and dutasteride, are approved for treating benign prostatic hyperplasia (BPH), and reduce prostate cancer risk by 25%. However, trials also…
Efficacy of Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Nonâmuscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial | Journal of Urology
Background:Nadofaragene firadenovec-vncg is a non-replicating adenoviral vectorâbased gene therapy for BCG-unresponsive carcinoma in situ (CIS) with/without HG Ta/T1). We report outcomes following 5 years of…
MP68-05âEXCESS DEATH AND POTENTIAL LIFE YEARS LOST AMONG BLACK PROSTATE CANCER PATIENTS (1970-2020) | Journal of Urology
INTRODUCTION AND OBJECTIVE:Prostate cancer demonstrates a wide and sustained disparity in mortality among Black Americans compared with the average US population. These disparities have persisted…
MP68-08âPHYSICIAN DENSITY AND PROSTATE CANCER MORTALITY IN THE US FROM 2011-2020 | Journal of Urology
INTRODUCTION AND OBJECTIVE:Prostate cancer is the second leading cause of cancer death in men in the United States, accounting for more than 34,000 deaths in…
Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial | Journal of Urology
Purpose:Efficacy and safety of vibegron, a β3-adrenergic receptor agonist, was assessed among men with symptoms of overactive bladder (OAB) receiving pharmacologic treatment for benign prostatic…
MP69-07âUROLOGIC COMPLICATIONS OF SODIUM-GLUCOSE CO-TRANSPORTER-2 (SGLT-2) INHIBITORS DIFFER BETWEEN DIABETIC MEN AND WOMEN | Journal of Urology
INTRODUCTION AND OBJECTIVE:Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are used for the treatment of hyperglycemia in patients with type 2 diabetes. Due to glucose filtration, SGLT-2 inhibitors…
Electrofulguration for Women With Uncomplicated Recurrent Urinary Tract Infections and Chronic Cystitis: Time for Trials! | Journal of Urology
Can’t sign in? Forgot your password? If the address matches an existing account you will receive an email with instructions to reset your password. Can’t…